Alkermes is a drug manufacturers - specialty & generic business based in the US. Alkermes shares (ALKS) are listed on the NASDAQ and all prices are listed in US Dollars. Alkermes employs 2,100 staff and has a trailing 12-month revenue of around $1.7 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $25.00 |
|---|---|
| 52-week range | $22.01 - $32.88 |
| 50-day moving average | $24.22 |
| 200-day moving average | $25.85 |
| Wall St. target price | $34.67 |
| PE ratio | 7.3899 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $3.36 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $25 from 2024-07-23
| 1 week (2024-07-17) | 1.58% |
|---|---|
| 1 month (2024-06-24) | 1.50% |
| 3 months (2024-04-24) | 1.42% |
| 6 months (2024-01-24) | -11.10% |
| 1 year (2023-07-24) | -21.36% |
|---|---|
| 2 years (2022-07-22) | -13.25% |
| 3 years (2021-07-23) | 2.12% |
| 5 years (2019-07-24) | 9.22% |
Valuing Alkermes stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alkermes's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alkermes's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Alkermes shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Alkermes's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $538.7 million.
The EBITDA is a measure of a Alkermes's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.7 billion |
|---|---|
| Operating margin TTM | 12.36% |
| Gross profit TTM | $893.7 million |
| Return on assets TTM | 14.65% |
| Return on equity TTM | 50.45% |
| Profit margin | 25.17% |
| Book value | $7.42 |
| Market Capitalization | $4.2 billion |
TTM: trailing 12 months
We're not expecting Alkermes to pay a dividend over the next 12 months.
Alkermes's shares were split on a 2:1 basis on 14 May 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Alkermes shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Alkermes shares which in turn could have impacted Alkermes's share price.
Over the last 12 months, Alkermes's shares have ranged in value from as little as $22.01 up to $32.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alkermes's is 0.437. This would suggest that Alkermes's shares are less volatile than average (for this exchange).
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N. V. , Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
A deep dive into the highlights and limitations of Frec.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.